Daniel J Weisdorf

List of Publications by Year
in descending order

849 papers	60,497 citations	952 115 h-index	1284 225 g-index
855 all docs	855 docs citations	855 times ranked	29666 citing authors

#	Article	IF	Citations
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2005, 11, 945-956.	2.0	3,213
2	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.	2.0	2,636
3	Acute Myeloid Leukemia. New England Journal of Medicine, 2015, 373, 1136-1152.	27.0	2,466
4	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105, 3051-3057.	1.4	1,574
5	Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 2000, 105, 71-77.	8.2	1,370
6	A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. New England Journal of Medicine, 1992, 326, 845-851.	27.0	1,175
7	High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood, 2007, 110, 4576-4583.	1.4	1,105
8	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	27.0	1,024
9	Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood, 2002, 100, 1611-1618.	1.4	970
10	Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 2005, 105, 1343-1347.	1.4	824
11	Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers. New England Journal of Medicine, 2004, 351, 2590-2598.	27.0	791
12	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. New England Journal of Medicine, 2012, 367, 1487-1496.	27.0	762
13	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood, 2014, 123, 3664-3671.	1.4	730
14	Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1999, 341, 14-21.	27.0	666
15	Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood, 2004, 104, 1923-1930.	1.4	638
16	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 2004, 104, 579-585.	1.4	638
17	Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood, 2001, 98, 2043-2051.	1.4	631
18	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood, 2012, 119, 2665-2674.	1.4	581

#	Article	IF	Citations
19	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	1.4	565
20	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 2012, 119, 296-307.	1.4	559
21	Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood, 2010, 116, 2411-2419.	1.4	541
22	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 2002, 100, 406-414.	1.4	503
23	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood, 2007, 110, 3064-3070.	1.4	489
24	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 1878-1887.	1.6	459
25	Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 2010, 116, 4693-4699.	1.4	456
26	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
27	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, 2009, 113, 726-732.	1.4	408
28	Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2004, 22, 1095-1102.	1.6	406
29	Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood, 2003, 102, 1915-1919.	1.4	397
30	Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood, 2015, 125, 1333-1338.	1.4	395
31	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. Journal of Clinical Oncology, 2010, 28, 3730-3738.	1.6	386
32	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 2020, 26, e177-e182.	2.0	378
33	Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biology of Blood and Marrow Transplantation, 2002, 8, 387-394.	2.0	367
34	Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigenâ€“matched unrelated donor bone marrow: results of a matched-pair analysis. Blood, 2001, 97, 2957-2961.	1.4	361
35	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood, 2014, 123, 3855-3863.	1.4	357
36	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood, 2002, 100, 3825-3827.	1.4	356

#	Article	IF	Citations
37	Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica, 2012, 97, 1916-1924.	3.5	355
38	Umbilical cord bloodâ€“derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood, 2016, 127, 1044-1051.	1.4	333
39	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. Journal of Immunology, 2012, 189, 5082-5088.	0.8	331
40	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
41	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood, 2011, 117, 4651-4657.	1.4	319
42	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 375-396.	2.0	316
43	Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood, 2007, 109, 1765-1772.	1.4	316
44	Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1987, 317, 461-467.	27.0	310
45	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527.	1.4	307
46	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clinical Cancer Research, 2016, 22, 3440-3450.	7.0	291
47	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood, 2009, 114, 4293-4299.	1.4	276
48	Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 2007, 109, 5058-5061.	1.4	270
49	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	1.6	265
50	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology, The, 2011, 12, 1195-1203.	10.7	263
51	Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow. Biology of Blood and Marrow Transplantation, 2002, 8, 257-260.	2.0	262
52	Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 454-459.	2.0	256
53	Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biology of Blood and Marrow Transplantation, 2003, 9, 657-666.	2.0	253
54	Parainfluenza Virus Respiratory Infection after Bone Marrow Transplantation. New England Journal of Medicine, 1992, 326, 921-926.	27.0	243

#	Article	IF	Citations
55	The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biology of Blood and Marrow Transplantation, 2006, 12, 876-884.	2.0	241
56	RISK FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION. Transplantation, 1991, 51, 1197-1202.	1.0	240
57	Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 473-485.	2.0	236
58	Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood, 2005, 105, 4215-4222.	1.4	234
59	A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematology,the, 2015, 2, e21-e29.	4.6	232
60	Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 340-340.	1.6	222
61	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood, 2014, 123, 3016-3026.	1.4	220
62	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
63	Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood, 2010, 116, 3129-3139.	1.4	210
64	Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood, 2002, 100, 1997-2004.	1.4	209
65	KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood, 2005, 106, 4370-4376.	1.4	208
66	Targeting Natural Killer Cells to Acute Myeloid LeukemiaIn Vitrowith a CD16 Ã— 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clinical Cancer Research, 2013, 19, 3844-3855.	7.0	208
67	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq1 1 0.784314 rgBT /Ove methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	4.6	200
68	Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome. American Journal of Medicine, 1994, 96, 497-503.	1.5	197
69	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood, 2011, 118, 4242-4249.	1.4	196
70	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. Biology of Blood and Marrow Transplantation, 2015, 21, 761-767.	2.0	195
71	Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood, 2002, 99, 1971-1977.	1.4	191
72	Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood, 2009, 113, 2410-2415.	1.4	191

#	Article	IF	Citations
73	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival. Biology of Blood and Marrow Transplantation, 2008, 14, 748-758.	2.0	186
74	Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood, 2003, 101, 2015-2023.	1.4	184
75	Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood, 2010, 115, 1850-1857.	1.4	184
76	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission. Biology of Blood and Marrow Transplantation, 2006, 12, 438-453.	2.0	182
77	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Network Open, 2021, 4, e2116901.	5.9	179
78	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first and second complete remission. Blood, 2010, 116, 366-374.	1.4	178
79	Acute graft-versus-host disease: a bench-to-bedside update. Blood, 2014, 124, 363-373.	1.4	178
80	Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival. Biology of Blood and Marrow Transplantation, 2007, 13, 1461-1468.	2.0	174
81	Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkinâ€™s Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 1065-1072.	2.0	171
82	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood, 2010, 116, 1839-1848.	1.4	168
83	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood, 2002, 100, 3479-3482.	1.4	167
84	Allogeneic natural killer cells for refractory lymphoma. Cancer Immunology, Immunotherapy, 2010, 59, 1739-1744.	4.2	166
85	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505.	2.0	165
86	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	5.2	164
87	Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood, 2011, 118, 5084-5095.	1.4	163
88	Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood, 2012, 119, 3854-3860.	1.4	163
89	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood, 2011, 117, 2307-2318.	1.4	161
90	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, 122, 3863-3870.	1.4	153

#	Article	IF	Citations
91	CYTOMEGALOVIRUS PNEUMONIA AFTER BONE MARROW TRANSPLANTATION. Transplantation, 1993, 55, 1339-1345.	1.0	148
92	Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood, 2006, 108, 3216-3222.	1.4	147
93	Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood, 2009, 113, 5628-5634.	1.4	147
94	A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality. Blood, 2014, 124, 188-188.	1.4	147
95	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2014, 32, 3264-3274.	1.6	146
96	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009, 113, 5074-5082.	1.4	143
97	Toward Biomarkers for Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 126-137.	2.0	139
98	Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia. Journal of Immunology, 2014, 192, 4592-4600.	0.8	139
99	Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood, 2001, 98, 2922-2929.	1.4	138
100	Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2002, 8, 40-46.	2.0	134
101	A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2000, 6, 441-447.	2.0	133
102	The best endpoint for acute GVHD treatment trials. Blood, 2010, 115, 5412-5417.	1.4	133
103	Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. British Journal of Haematology, 1983, 55, 691-700.	2.5	132
104	Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood, 2003, 102, 802-809.	1.4	132
105	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	4.6	132
106	Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2001, 7, 265-273.	2.0	130
107	Diffuse Alveolar Hemorrhage and Infection-Associated Alveolar Hemorrhage following Hematopoietic Stem Cell Transplantation: Related and High-Risk Clinical Syndromes. Biology of Blood and Marrow Transplantation, 2006, 12, 1038-1046.	2.0	130
108	Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2012, 18, 1727-1733.	2.0	129

#	Article	IF	Citations
109	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 2011, 117, 6714-6720.	1.4	128
110	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 359-370.	2.0	127
111	Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2012, 55, 764-770.	5.8	124
112	Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood, 2012, 119, 5591-5598.	1.4	124
113	Prophylactic antibiotics for the prevention of early infection in multiple myeloma. American Journal of Medicine, 1996, 100, 624-628.	1.5	123
114	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation, 2011, 17, 1796-1803.	2.0	123
115	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. Biology of Blood and Marrow Transplantation, 2008, 14, 282-289.	2.0	119
116	HEMORRHAGIC CYSTITIS AFTER BONE MARROW TRANSPLANTATION RISK FACTORS AND COMPLICATIONS. Transplantation, 1993, 56, 875-879.	1.0	113
117	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Nonâ€“Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 6168-6174.	7.0	111
118	Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources. Biology of Blood and Marrow Transplantation, 2007, 13, 1106-1115.	2.0	108
119	Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood, 2009, 113, 2902-2905.	1.4	106
120	Avascular necrosis of bone: A common serious complication of allogeneic bone marrow transplantation. American Journal of Medicine, 1990, 89, 733-738.	1.5	105
121	Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research. Journal of Clinical Oncology, 2005, 23, 5788-5794.	1.6	104
122	Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient. Biology of Blood and Marrow Transplantation, 2009, 15, 249-256.	2.0	104
123	Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood, 2006, 107, 3804-3807.	1.4	103
124	A Randomized Trial of the Effect of a Walking Regimen on the Functional Status of 100 Adult Allogeneic Donor Hematopoietic Cell Transplant Patients. Biology of Blood and Marrow Transplantation, 2007, 13, 948-955.	2.0	101
125	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 871-890.	2.0	101
126	Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation: Report from the Bone Marrow Transplantation Survivor Study. Biology of Blood and Marrow Transplantation, 2013, 19, 1073-1080.	2.0	101

#	Article	IF	Citations
127	The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Experimental Hematology, 2001, 29, 1336-1346.	0.4	100
128	HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 1644-1652.	1.6	100
129	Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology, 1989, 9, 443-448.	7.3	99
130	Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood, 2005, 106, 3308-3313.	1.4	99
131	Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant Complications. Biology of Blood and Marrow Transplantation, 2009, 15, 564-573.	2.0	99
132	Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood, 2010, 115, 5041-5052.	1.4	98
133	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clinical Cancer Research, 2015, 21, 2020-2028.	7.0	98
134	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients. JAMA Oncology, 2016, 2, 1277.	7.1	93
135	Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British Journal of Haematology, 2002, 119, 1115-1124.	2.5	92
136	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. Journal of Clinical Oncology, 2009, 27, 3634-3641.	1.6	92
137	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood, 2014, 124, 3221-3227.	1.4	92
138	Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood, 2015, 125, 3798-3804.	1.4	90
139	Pretransplantation Burden of Leukemic Progenitor Cells as a Predictor of Relapse after Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1993, 329, 1296-1301.	27.0	89
140	Graft-versus-Host Disease Treatment: Predictors of Survival. Biology of Blood and Marrow Transplantation, 2010, 16, 1693-1699.	2.0	89
141	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1183-1189.	2.0	89
142	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	5.2	89
143	Toxic Leukoencephalopathy following Fludarabine-Associated Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 300-308.	2.0	87
144	Human Herpesvirus 6 Infection after Hematopoietic Cell Transplantation: Is Routine Surveillance Necessary?. Biology of Blood and Marrow Transplantation, 2011, 17, 1562-1568.	2.0	87

#	Article	IF	Citations
145	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	3.5	87
146	PREDNISONE THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE. Transplantation, 1993, 56, 577-580.	1.0	86
147	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Advances, 2018, 2, 1459-1469.	5.2	85
148	SIMULTANEOUS UPPER AND LOWER ENDOSCOPIC BIOPSY IN THE DIAGNOSIS OF INTESTINAL GRAFT-VERSUS-HOST DISEASE. Transplantation, 1991, 51, 642-645.	1.0	84
149	Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biology of Blood and Marrow Transplantation, 2001, 7, 395-399.	2.0	83
150	A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood, 2007, 109, 2657-2662.	1.4	83
151	What predicts high risk acute graftâ€versusâ€host disease (<scp>GVHD</scp>) at onset?: identification of those at highest risk by a novel acute <scp>GVHD</scp> risk score. British Journal of Haematology, 2012, 157, 732-741.	2.5	83
152	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2021, 39, 1888-1898.	1.6	83
153	Chronic graft-versus-host disease: A prospective cohort study. Biology of Blood and Marrow Transplantation, 2003, 9, 38-45.	2.0	81
154	Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forÂInternational Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2012, 18, 280-288.	2.0	81
155	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 1355-1360.	2.0	81
156	Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood, 2008, 112, 426-434.	1.4	80
157	Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 816-822.	2.0	80
158	A survey of diagnosis, management, and grading of chronic GVHD. Biology of Blood and Marrow Transplantation, 2002, 8, 32-39.	2.0	78
159	National marrow donor program HLA-matching guidelines for unrelated marrow transplants. Biology of Blood and Marrow Transplantation, 2003, 9, 610-615.	2.0	78
160	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. Biology of Blood and Marrow Transplantation, 2014, 20, 858-864.	2.0	78
161	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica, 2012, 97, 451-458.	3.5	77
162	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77

#	Article	IF	Citations
163	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2010, 16, 1187-1211.	2.0	76
164	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 337-344.	2.0	76
165	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
166	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Advances, 2018, 2, 909-922.	5.2	76
167	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	7.2	76
168	Viridans streptococcal shock in bone marrow transplantation patients. American Journal of Hematology, 1993, 42, 354-358.	4.1	74
169	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunology, Immunotherapy, 2018, 67, 483-494.	4.2	74
170	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. British Journal of Haematology, 1997, 96, 749-756.	2.5	72
171	Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 287-291.	2.0	72
172	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	4.1	72
173	Fluconazole to prevent yeast infections in bone marrow transplantation patients:. American Journal of Medicine, 2002, 112, 369-379.	1.5	71
174	Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2004, 10, 655-668.	2.0	71
175	Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clinical Pharmacology and Therapeutics, 2005, 78, 486-500.	4.7	71
176	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1636-1645.	2.0	71
177	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
178	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
179	Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse. Biology of Blood and Marrow Transplantation, 2012, 18, 106-112.	2.0	70
180	Ibuprofen inhibits granulocyte responses to inflammatory mediators. Inflammation, 1984, 8, 33-44.	3.8	69

#	Article	IF	Citations
181	Red Blood Cell (RBC) and Platelet (PLT) Transfusion after Allogeneic Transplant for Leukemia: Similar Utilization after Sibling (SIB) Peripheral Blood Stem Cell (PBSC) and Umbilical Cord Blood (UCB) Graft.. Blood, 2005, 106, 1755-1755.	1.4	69
182	CMV antigenemia following bone marrow transplantation: Risk factors and outcomes. Biology of Blood and Marrow Transplantation, 2000, 6, 280-288.	2.0	68
183	Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: RiskÂFactors, Management, Mortality, and ChangesÂoverÂTime. Biology of Blood and Marrow Transplantation, 2012, 18, 1580-1588.	2.0	68
184	Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 134-140.	2.0	68
185	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2005, 11, 823-861.	2.0	67
186	Acute Radiation Injury: Contingency Planning for Triage, Supportive Care, and Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 672-682.	2.0	67
187	A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. Biology of Blood and Marrow Transplantation, 2003, 9, 52-59.	2.0	66
188	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical Cord Blood and Matched Related Donor Transplants. Biology of Blood and Marrow Transplantation, 2008, 14, 985-992.	2.0	66
189	Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. American Journal of Medicine, 2001, 110, 339-346.	1.5	65
190	A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research, 2004, 28, 559-565.	0.8	65
191	Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program. Biology of Blood and Marrow Transplantation, 2007, 13, 844-852.	2.0	65
192	Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). Biology of Blood and Marrow Transplantation, 2008, 14, 1017-1021.	2.0	65
193	Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood, 2008, 111, 5440-5445.	1.4	65
194	TREATMENT OF MODERATE AND SEVERE ACUTE GVHD AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1994, 58, 437-442.	1.0	64
195	Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Advances, 2019, 3, 897-907.	5.2	64
196	Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival. Biology of Blood and Marrow Transplantation, 2008, 14, 1394-1400.	2.0	63
197	Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biology of Blood and Marrow Transplantation, 2003, 9, 512-518.	2.0	62
198	Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. Biology of Blood and Marrow Transplantation, 2009, 15, 777-784.	2.0	62

#	Article	IF	Citations
199	Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1021-1025.	2.0	61
200	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. American Journal of Hematology, 2007, 82, 867-872.	4.1	60
201	Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. Clinical Cancer Research, 2015, 21, 1267-1272.	7.0	60
202	Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes. Biology of Blood and Marrow Transplantation, 2002, 8, 213-220.	2.0	59
203	Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB). Biology of Blood and Marrow Transplantation, 2007, 13, 1145-1152.	2.0	59
204	Adaptive NK cell reconstitution is associated with better clinical outcomes. JCI Insight, 2019, 4, .	5.0	59
205	Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation, 2001, 7, 674-679.	2.0	58
206	Granulocytes utilize different energy sources for movement and phagocytosis. Inflammation, 1982, 6, 245-256.	3.8	57
207	Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. British Journal of Haematology, 2006, 132, 755-769.	2.5	56
208	Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 538-545.	2.0	56
209	Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 831-840.	2.0	56
210	Treatment of relapsed/refractory acute myeloid leukaemia in adults. British Journal of Haematology, 2018, 181, 27-37.	2.5	56
211	Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1327-1334.	2.0	54
212	Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 669-675.	2.0	54
213	Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. British Journal of Haematology, 1994, 86, 62-69.	2.5	53
214	Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2011, 17, 1765-1774.	2.0	53
215	Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biology of Blood and Marrow Transplantation, 2015, 21, 1029-1036.	2.0	53
216	Morphologic and Quantitative Changes in Blood and Marrow Cells Following Growth Factor Therapy. American Journal of Clinical Pathology, 1994, 101, 67-75.	0.7	52

#	Article	IF	Citations
217	Introduction: 20th Anniversary of the NMDP. Biology of Blood and Marrow Transplantation, 2008, 14, 1.	2.0	52
218	Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, 356-364.	2.0	52
219	Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood, 2011, 118, 4472-4479.	1.4	52
220	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1341-1348.	2.0	52
221	Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation. Current Medical Research and Opinion, 2019, 35, 983-988.	1.9	52
222	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. Biology of Blood and Marrow Transplantation, 2008, 14, 187-196.	2.0	51
223	The National Marrow Donor Programâ€™s Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment. Biology of Blood and Marrow Transplantation, 2012, 18, 172-182.	2.0	51
224	Coreâ€binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. American Journal of Hematology, 2014, 89, 1121-1131.	4.1	51
225	â€œWorldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registriesâ€. Bone Marrow Transplantation, 2019, 54, 1179-1188.	2.4	51
226	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
227	Prolonged subcutaneous administration of 852A, a novel systemic tollâ€like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. American Journal of Hematology, 2012, 87, 953-956.	4.1	50
228	Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance. Biology of Blood and Marrow Transplantation, 2013, 19, 102-108.	2.0	50
229	Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica, 2013, 98, 185-192.	3.5	50
230	Assessment of Joint and Fascia Manifestations in Chronic Graftâ€Versusâ€Host Disease. Arthritis and Rheumatology, 2014, 66, 1044-1052.	5.6	50
231	Adaptive Natural Killer Cell and Killer Cell Immunoglobulinâ€“Like Receptorâ€“Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1653-1662.	2.0	50
232	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2020, 26, 1312-1317.	2.0	49
233	INTERLEUKIN 2 IMMEDIATELY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIAâ€“A PHASE I STUDY. Transplantation, 1993, 55, 61-66.	1.0	48
234	Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation, 2004, 10, 395-404.	2.0	48

#	Article	IF	Citations
235	Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. American Journal of Hematology, 2008, 83, 446-450.	4.1	48
236	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica, 2011, 96, 1528-1535.	3.5	48
237	Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival. Biology of Blood and Marrow Transplantation, 2012, 18, 963-968.	2.0	48
238	Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation, 2015, 21, 2052-2060.	2.0	48
239	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer, 2017, 123, 2025-2034.	4.1	48
240	The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkinâ€™s Lymphoma in Second Complete or Partial Remission. Biology of Blood and Marrow Transplantation, 2007, 13, 486-492.	2.0	47
241	Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood, 2012, 119, 4083-4090.	1.4	47
242	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 1517-1524.	2.0	47
243	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	2.4	47
244	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Advances, 2020, 4, 2810-2820.	5.2	47
245	INFECTIONS IN RECIPIENTS OF BLOOD AND MARROW TRANSPLANTATION. Hematology/Oncology Clinics of North America, 1999, 13, 1065-1089.	2.2	46
246	Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match. Biology of Blood and Marrow Transplantation, 2008, 14, 1334-1340.	2.0	46
247	Costs of pediatric allogeneic hematopoieticâ€cell transplantation. Pediatric Blood and Cancer, 2010, 54, 138-143.	1.5	46
248	Reduced intensity conditioned allograft yields favorable survival for older adults with Bâ€cell acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 42-49.	4.1	46
249	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
250	High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation, 2003, 76, 1758-1762.	1.0	45
251	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 487-492.	2.0	44
252	GVHDâ€”The Nuts and Bolts. Hematology American Society of Hematology Education Program, 2007, 2007, 62-67.	2.5	43

#	Article	IF	Citations
253	Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 480-486.	2.0	43
254	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood, 2016, 128, 2350-2358.	1.4	43
255	Effect of Infusion Rate on Amphotericin B-Associated Febrile Reactions. Drug Intelligence & Clinical Pharmacy, 1988, 22, 769-772.	0.4	42
256	Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. British Journal of Haematology, 2003, 121, 597-604.	2.5	42
257	Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 789-791.	2.0	42
258	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	5.2	42
259	Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 440-443.	2.0	41
260	Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome. Biology of Blood and Marrow Transplantation, 2011, 17, 1497-1504.	2.0	41
261	Complement Fragment 3a Priming of Umbilical Cord Blood Progenitors: Safety Profile. Biology of Blood and Marrow Transplantation, 2013, 19, 1474-1479.	2.0	41
262	Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type. Biology of Blood and Marrow Transplantation, 2015, 21, 357-363.	2.0	41
263	Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1602-1607.	2.0	41
264	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 1771-1779.	5.8	41
265	Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants. Biology of Blood and Marrow Transplantation, 2011, 17, 710-716.	2.0	40
266	Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1110-1116.	2.0	40
267	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. Biology of Blood and Marrow Transplantation, 2009, 15, 1475-1478.	2.0	39
268	National Cancer Instituteâ€™s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2011, 17, 443-454.	2.0	39
269	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1024-1029.	2.0	39
270	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. JAMA Oncology, 2020, 6, 486.	7.1	39

#	Article	IF	Citations
271	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Advances, 2021, 5, 1425-1436.	5.2	39
272	Influence of Total Body Irradiation Dose Rate on Idiopathic Pneumonia Syndrome in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. International Journal of Radiation Oncology Biology Physics, 2019, 103, 180-189.	0.8	38
273	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, e161-e166.	2.0	38
274	Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors withÂan Activating KIR Genotype. Biology of Blood and Marrow Transplantation, 2010, 16, 1155-1161.	2.0	37
275	Allotransplantation for Patients Age â‰¥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
276	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1589-1596.	2.0	37
277	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
278	THERAPEUTIC RAMIFICATIONS OF THE INTERACTION OF COMPLEMENT, GRANULOCYTES, AND PLATELETS IN THE PRODUCTION OF ACUTE LUNG INJURY. Annals of the New York Academy of Sciences, 1982, 384, 489-495.	3.8	36
279	Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 214-222.	2.0	36
280	Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 138-142.	2.0	36
281	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
282	Late-Onset Noninfectious Pulmonary Complications in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Transplantation, 2011, 91, 798-803.	1.0	36
283	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Blood, 2019, 134, 2035-2035.	1.4	36
284	Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Experimental Hematology, 2000, 28, 96-103.	0.4	35
285	HLA match likelihoods for Indian patients seeking unrelated donor transplantation grafts: a population-based study. Lancet Haematology,the, 2014, 1, e57-e63.	4.6	35
286	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 926-933.	2.0	35
287	The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplantation, 2020, 55, 2043-2044.	2.4	35
288	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35

#	Article	IF	Citations
289	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
290	Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium. Biology of Blood and Marrow Transplantation, 2013, 19, 967-972.	2.0	34
291	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica, 2018, 103, 1915-1924.	3.5	34
292	Risk of Relapse (REL) after Umbilical Cord Blood Transplantation (UCBT) in Patients with Acute Leukemia: Marked Reduction in Recipients of Two Units.. Blood, 2005, 106, 305-305.	1.4	34
293	A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biology of Blood and Marrow Transplantation, 1999, 5, 386-393.	2.0	33
294	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
295	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
296	Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades. JAMA Oncology, 2021, 7, 1626.	7.1	33
297	Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children. British Journal of Haematology, 1988, 69, 351-358.	2.5	32
298	THE IMMUNOPATHOLOGY OF UPPER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE LYMPHOID CELLS AND ENDOTHELIAL ADHESION MOLECULES. Transplantation, 1993, 55, 572-577.	1.0	32
299	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2010, 16, 421-429.	2.0	32
300	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2011, 17, 1025-1032.	2.0	32
301	Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 2297-2302.	2.0	32
302	Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia. Scientific Reports, 2019, 9, 6083.	3.3	32
303	Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome, 2021, 9, 211.	11.1	32
304	The Importance of Surveillance Stool Cultures During Periods of Severe Neutropenia. Infection Control, 1987, 8, 317-319.	0.1	31
305	Late infections following allogeneic bone marrow transplantation: Suggested strategies for prophylaxis. Leukemia and Lymphoma, 1997, 26, 1-15.	1.3	31
306	Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source. Biology of Blood and Marrow Transplantation, 2017, 23, 795-804.	2.0	31

#	Article	IF	Citations
307	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplantation, 2019, 54, 402-417.	2.4	31
308	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. Blood, 2010, 116, 37-37.	1.4	31
309	Patient interleukinâ€18 GCG haplotype associates with improved survival and decreased transplantâ€related mortality after unrelatedâ€donor bone marrow transplantation. British Journal of Haematology, 2004, 126, 704-710.	2.5	30
310	Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy. Leukemia, 2020, 34, 312-316.	7.2	30
311	Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation. Cancer, 2020, 126, 1434-1447.	4.1	30
312	THE TISSUE EXPRESSION OF CYTOKINES IN HUMAN ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE. Transplantation, 1995, 60, 343-347.	1.0	29
313	Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation. Journal of Clinical Pharmacology, 2007, 47, 6-12.	2.0	29
314	Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation. British Journal of Haematology, 1989, 71, 409-413.	2.5	29
315	Similar Risks for Chronic Kidney Disease in Long-Term Survivors of Myeloablative and Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 658-663.	2.0	29
316	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 2014, 99, 1618-1623.	3.5	29
317	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica, 2015, 100, 690-695.	3.5	29
318	A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT). Therapeutic Drug Monitoring, 2006, 28, 394-401.	2.0	28
319	The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2010, 16, 253-262.	2.0	28
320	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Current Topics in Microbiology and Immunology, 2015, 395, 225-243.	1.1	28
321	Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged â‰¥70ÂYears. Biology of Blood and Marrow Transplantation, 2016, 22, 390-393.	2.0	28
322	KIR Donor Selection: Feasibility in Identifying better Donors. Biology of Blood and Marrow Transplantation, 2019, 25, e28-e32.	2.0	28
323	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	7.2	28
324	Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure. American Journal of Hematology, 2015, 90, 892-896.	4.1	27

#	Article	IF	Citations
325	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitorâ€“Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2025-2030.	2.0	27
326	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Advances, 2018, 2, 1882-1888.	5.2	27
327	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. JAMA Oncology, 2018, 4, e182453.	7.1	27
328	Hematopoietic Cell Transplantâ€“Related Toxicities and Mortality in Frail Recipients. Biology of Blood and Marrow Transplantation, 2019, 25, 2454-2460.	2.0	27
329	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Advances, 2019, 3, 2581-2585.	5.2	27
330	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Advances, 2021, 5, 975-983.	5.2	27
331	Treatment of refractory and relapsed Hodgkin's disease: Intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Medical and Pediatric Oncology, 1990, 18, 447-453.	1.0	26
332	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 124-132.	2.0	26
333	Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplantation Outcomes in Patients withÂAcute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, 930-936.	2.0	26
334	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2015, 126, 739-739.	1.4	26
335	No evidence for colonization of oral bacteria in the distal gut in healthy adults. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
336	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 2022, 28, 409.e1-409.e10.	1.2	26
337	Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 2005, 11, 129-135.	2.0	25
338	T Cellâ€“Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome. Biology of Blood and Marrow Transplantation, 2012, 18, 937-943.	2.0	25
339	Hematopoietic Stem Cell Transplantation in Patients with Systolic Dysfunction: Can It Be Done?. Biology of Blood and Marrow Transplantation, 2015, 21, 300-304.	2.0	25
340	Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Biology of Blood and Marrow Transplantation, 2016, 22, 1133-1137.	2.0	25
341	Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with Bâ€Cell acute lymphoblastic leukemia. Cancer, 2017, 123, 3346-3355.	4.1	25
342	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25

#	Article	IF	Citations
343	IL-15 ADMINISTRATION FOLLOWING SYNGENEIC BONE MARROW TRANSPLANTATION PROLONGS SURVIVAL OF LYMPHOMA BEARING MICE1. Transplantation, 1996, 62, 872-875.	1.0	25
344	Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. Biology of Blood and Marrow Transplantation, 2008, 14, 685-692.	2.0	24
345	Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. Radiotherapy and Oncology, 2016, 118, 65-71.	0.6	24
346	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood, 2011, 118, 1-1.	1.4	24
347	Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. American Journal of Hematology, 2006, 81, 519-524.	4.1	23
348	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. Biology of Blood and Marrow Transplantation, 2015, 21, 640-645.	2.0	23
349	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 879-883.	2.0	23
350	Alternative donor transplantation for acute myeloid leukemia in patients aged â‰¥50 years: young HLA-matched unrelated or haploidentical donor?. Haematologica, 2020, 105, 407-413.	3.5	23
351	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	3.5	23
352	RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH INHERITED DEFICIENCY OF HEPARIN COFACTOR II. British Journal of Haematology, 1991, 77, 125-126.	2.5	22
353	Unrelated Donor Bone Marrow Transplantation for Hematological Malignancies-Current Status. Leukemia and Lymphoma, 1996, 23, 221-226.	1.3	22
354	Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Translational Research, 2016, 175, 103-115.e4.	5.0	22
355	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica, 2016, 101, 1267-1274.	3.5	22
356	Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing Unanswered Questions. Biology of Blood and Marrow Transplantation, 2007, 13, 257-262.	2.0	21
357	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21
358	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
359	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Advances, 2020, 4, 1284-1295.	5.2	21
360	Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature. American Journal of Medicine, 2002, 113, 152-155.	1.5	20

#	Article	IF	Citations
361	Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation, 2006, 12, 204-216.	2.0	20
362	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica, 2016, 101, 764-772.	3.5	20
363	The role of second transplants for leukemia. Best Practice and Research in Clinical Haematology, 2016, 29, 359-364.	1.7	20
364	Reduced-intensity versus myeloablative allogeneic transplantation. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 321-326.	0.9	20
365	Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics. Haematologica, 2018, 103, 2109-2115.	3.5	20
366	Auer rod positive dysmyelopoietic syndrome. American Journal of Hematology, 1981, 11, 397-402.	4.1	19
367	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 866-872.	2.0	19
368	Positron Emission Tomographyâ€"Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 64-70.	2.0	19
369	Antibiotic practice patterns in hematopoietic cell transplantation: A survey of blood and marrow transplant clinical trials network centers. American Journal of Hematology, 2018, 93, E348-E350.	4.1	19
370	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2372-2377.	2.0	19
371	GTB-3550 TriKEâ„¢ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts. Blood, 2020, 136, 7-8.	1.4	19
372	Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: A prospective, comparative trial. , 1997, 54, 202-208.		18
373	Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2014, 55, 358-364.	1.3	18
374	Proteome Profiling in Lung Injury after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1383-1390.	2.0	18
375	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
376	Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. ESMO Open, 2020, 5, e000803.	4.5	18
377	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 911-917.	2.4	18
378	Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. British Journal of Haematology, 2002, 118, 101-107.	2.5	17

#	Article	IF	Citations
379	Peritransplant palifermin use and lymphocyte recovery after Tâ€cell replete, matched related allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2011, 86, 879-882.	4.1	17
380	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. Biology of Blood and Marrow Transplantation, 2013, 19, 1102-1108.	2.0	17
381	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. American Journal of Hematology, 2017, 92, 1032-1036.	4.1	17
382	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq0 0 0 rgBT /Overloc	2.8	17
383	Pediatric acute GVHD: clinical phenotype and response to upfront steroids. Bone Marrow Transplantation, 2020, 55, 165-171.	2.4	17
384	Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 600-605.	2.0	17
385	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 270.e1-270.e6.	1.2	17
386	Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?. Current Opinion in Hematology, 2010, 17, 133-138.	2.5	16
387	Radiation Injury Treatment Network (RITN): Healthcare professionals preparing for a mass casualty radiological or nuclear incident. International Journal of Radiation Biology, 2011, 87, 748-753.	1.8	16
388	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	1.4	16
389	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leukemia Research, 1998, 22, 973-981.	0.8	15
390	Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. British Journal of Haematology, 2007, 137, 152-157.	2.5	15
391	Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood, 2011, 117, 5261-5263.	1.4	15
392	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. Haematologica, 2017, 102, 941-947.	3.5	15
393	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	5.2	15
394	Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. gallinarum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Blood and Marrow Transplantation, 2018, 24, 1260-1263.	2.0	15
395	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Advances, 2019, 3, 230-236.	5.2	15
396	Special report: Summary of the first meeting of African Blood and Marrow Transplantation (AfBMT) group, Casablanca, Morocco, April 19â€“21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT). Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 202-207.	0.9	15

#	Article	IF	Citations
397	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
398	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
399	Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells. Blood, 2008, 112, 827-827.	1.4	15
400	Digital integration of granulocyte aggregation responses. Inflammation, 1980, 4, 381-395.	3.8	14
401	Association between Genetic Variants in the Base Excision Repair Pathway and Outcomes after Hematopoietic Cell Transplantations. Biology of Blood and Marrow Transplantation, 2010, 16, 1084-1089.	2.0	14
402	Multi-institutional Feasibility Study of a Fast Patient Localization Method in Total Marrow Irradiation With Helical Tomotherapy: A Global Health Initiative by the International Consortium of Total Marrow Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 30-38.	0.8	14
403	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for I nternational B lood and M arrow T ransplant R esearch cohort analysis. Cancer, 2017, 123, 2035-2042.	4.1	14
404	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Advances, 2019, 3, 2465-2469.	5.2	14
405	Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage. Health Affairs, 2019, 38, 1887-1892.	5.2	14
406	Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 883-890.	2.0	14
407	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.9	14
408	Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica, 2020, 105, 519-524.	3.5	14
409	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. Blood Advances, 2021, 5, 1352-1359.	5.2	14
410	Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood, 2010, 116, 41-41.	1.4	14
411	Prolonged Remissions with Autologous and Allogeneic Stem Cell Transplantation for Burkittâ€™s Lymphoma: Long Term Follow-Up at a Single Institution.. Blood, 2005, 106, 1133-1133.	1.4	14
412	Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System. Blood, 2012, 120, 2011-2011.	1.4	14
413	Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning. Clinical Pharmacology and Therapeutics, 1978, 24, 663-667.	4.7	13
414	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leukemia Research, 1999, 23, 709-718.	0.8	13

#	Article	IF	Citations
415	Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 171-177.	2.0	13
416	Chronic graft-versus-host disease: where is promise for the future?. Leukemia, 2005, 19, 1532-1535.	7.2	13
417	Providing Personalized Prognostic Information for Adult Leukemia Survivors. Biology of Blood and Marrow Transplantation, 2013, 19, 1600-1607.	2.0	13
418	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	3.5	13
419	Pre-transplant recovery of microbiome diversity without recovery of the original microbiome. Bone Marrow Transplantation, 2019, 54, 1115-1117.	2.4	13
420	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation, 2020, 26, 1137-1143.	2.0	13
421	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	2.4	13
422	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2018, 24, 618-622.	2.0	13
423	Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2008, 112, 346-346.	1.4	13
424	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	1.2	13
425	High Unbound Mycophenolic Acid Concentrations in a Hematopoietic Cell Transplantation Patient with Sepsis and Renal and Hepatic Dysfunction. Biology of Blood and Marrow Transplantation, 2005, 11, 977-978.	2.0	12
426	Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leukemia Research, 2011, 35, 757-761.	0.8	12
427	Which donor or graft source should you choose for the strongest GVL? Is there really any difference. Best Practice and Research in Clinical Haematology, 2013, 26, 293-296.	1.7	12
428	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
429	Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 944-948.	2.0	12
430	First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, S175-S176.	2.0	12
431	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
432	Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. Journal of Clinical Oncology, 2020, 38, 2872-2882.	1.6	12

#	Article	IF	Citations
433	Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Supportive Care in Cancer, 2020, 28, 5491-5499.	2.2	12
434	Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 310.e1-310.e6.	1.2	12
435	Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia. Blood Advances, 2021, 5, 3937-3950.	5.2	12
436	High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.. Blood, 2007, 110, 171-171.	1.4	12
437	Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 372.e1-372.e9.	1.2	12
438	Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. British Journal of Haematology, 2012, 156, 273-275.	2.5	11
439	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 825-833.	2.0	11
440	Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. American Journal of Hematology, 2017, 92, E66-E68.	4.1	11
441	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11
442	Levaquin Gets a Pass. Biology of Blood and Marrow Transplantation, 2020, 26, 778-781.	2.0	11
443	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 373-385.	1.6	11
444	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
445	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. Blood, 2015, 126, 193-193.	1.4	11
446	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. Journal of Clinical Oncology, 2022, 40, 1991-2003.	1.6	11
447	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigenâ€“Matched Grafts. Biology of Blood and Marrow Transplantation, 2017, 23, 126-133.	2.0	10
448	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. Blood, 2018, 131, 2720-2729.	1.4	10
449	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 2190-2196.	2.0	10
450	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. Modern Pathology, 2019, 32, 560-567.	5.5	10

#	Article	IF	Citations
451	Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 2329-2334.	2.0	10
452	Effect of COVID-19 precautions on the gut microbiota and nosocomial infections. Gut Microbes, 2021, 13, 1-10.	9.8	10
453	Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis. Current Medical Research and Opinion, 2021, 37, 755-759.	1.9	10
454	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Advances, 2021, 5, 4102-4111.	5.2	10
455	Cardiac Imaging Methods for Chemotherapy-related Cardiotoxicity Screening and Related Radiation Exposure: Current Practice and Trends. Anticancer Research, 2017, 37, 2445-2449.	1.1	10
456	Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Transplantation and Cellular Therapy, 2021, 28, 88-88.	1.2	10
457	Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Advances, 2022, 6, 3451-3457.	5.2	10
458	Influence of dietary omega-3 fatty acids on granulocyte function. Inflammation, 1982, 6, 227-234.	3.8	9
459	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leukemia Research, 1999, 23, 817-826.	0.8	9
460	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. Biology of Blood and Marrow Transplantation, 2010, 16, 1436-1441.	2.0	9
461	An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 81-88.	2.0	9
462	Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey. Biology of Blood and Marrow Transplantation, 2016, 22, 1717-1720.	2.0	9
463	Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. American Journal of Hematology, 2017, 92, E529-E533.	4.1	9
464	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biology of Blood and Marrow Transplantation, 2019, 25, 56-62.	2.0	9
465	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2261-2266.	2.0	9
466	Risk of venous thromboembolism in patients with nonâ€Hodgkin lymphoma surviving blood or marrow transplantation. Cancer, 2019, 125, 4498-4508.	4.1	9
467	Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1884-1889.	2.0	9
468	Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Translational Research, 2020, 220, 167-181.	5.0	9

#	Article	IF	Citations
469	Non-Myeloablative (NMA) Umbilical Cord Blood Transplantation (UCBT): Promising Disease-Free Survival in 95 Consecutive Patients.. Blood, 2005, 106, 559-559.	1.4	9
470	Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. Blood, 2008, 112, 348-348.	1.4	9
471	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. Blood, 2012, 120, 894-894.	1.4	9
472	Health-Related Quality of Life (HRQL) in Adult Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2004, 104, 2254-2254.	1.4	9
473	Infusions of interleukin-1? after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. Journal of Clinical Immunology, 1994, 14, 205-211.	3.8	8
474	Allogeneic stem cell transplantation in first complete remission. Current Opinion in Hematology, 2011, 18, 395-400.	2.5	8
475	Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica, 2018, 103, 1708-1719.	3.5	8
476	Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy. PLoS ONE, 2019, 14, e0223890.	2.5	8
477	Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 949-954.	2.0	8
478	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. Biology of Blood and Marrow Transplantation, 2020, 26, e138-e141.	2.0	8
479	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplantation, 2020, 55, 1975-1984.	2.4	8
480	Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01. Journal of Immunology, 2021, 206, 3064-3072.	0.8	8
481	Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. Transplant Infectious Disease, 2022, 24, e13720.	1.7	8
482	Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. Blood, 2020, 136, 1-2.	1.4	8
483	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions To Predict Survival.. Blood, 2007, 110, 45-45.	1.4	8
484	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.. Blood, 2009, 114, 3416-3416.	1.4	8
485	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. Blood, 2014, 124, 679-679.	1.4	8
486	Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion. Blood, 2015, 126, 232-232.	1.4	8

#	Article	IF	Citations
487	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics. Blood, 2016, 128, 4291-4291.	1.4	8
488	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. Blood, 2004, 104, 1825-1825.	1.4	8
489	Radiation Emergencies: Evaluation, Management, and Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 103-106.	2.0	7
490	Does highâ€dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. American Journal of Hematology, 2013, 88, 533-534.	4.1	7
491	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for venoâ€occlusive disease?. European Journal of Haematology, 2016, 96, 655-657.	2.2	7
492	Adjusting Cyclophosphamide Dose in Obese Patients withÂLymphoma Is Safe and Yields Favorable Outcomes afterÂAutologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 571-574.	2.0	7
493	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biology of Blood and Marrow Transplantation, 2017, 23, 1485-1490.	2.0	7
494	Vorinostat is victorious in GVHD prevention. Blood, 2017, 130, 1690-1691.	1.4	7
495	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
496	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. Cancer, 2020, 126, 3322-3329.	4.1	7
497	Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Transplantation and Cellular Therapy, 2021, 27, 84.e1-84.e5.	1.2	7
498	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. Cancer, 2021, 127, 794-800.	4.1	7
499	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. Bone Marrow Transplantation, 2021, 56, 1373-1380.	2.4	7
500	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208). Blood, 2019, 134, 872-872.	1.4	7
501	Pregnancy Outcomes after Hematopoietic Cell Transplantation (HCT): A Report from the BMT Survivor Study.. Blood, 2004, 104, 58-58.	1.4	7
502	Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. Blood, 2010, 116, 526-526.	1.4	7
503	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15RÎ±-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. Blood, 2015, 126, 1957-1957.	1.4	7
504	Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy. Blood, 2021, 138, 230-230.	1.4	7

#	Article	IF	Citations
505	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. Journal of Clinical Oncology, 0, , .	1.6	7
506	In vitro correlates of low dose Ara-C efficacy: Clinical, cytogenetic, and bone marrow culture analysis. American Journal of Hematology, 1987, 25, 43-53.	4.1	6
507	Analysis of failure times for multiple infections following bone marrow transplantation: an application of the multiple failure time proportional hazards model. , 1998, 17, 2371-2380.		6
508	Graft vs. host disease: pathology, prophylaxis and therapy. Best Practice and Research in Clinical Haematology, 2008, 21, 99-100.	1.7	6
509	MEDICAL MANAGEMENT OF RADIATION VICTIMS IN THE UNITED STATES. Health Physics, 2010, 98, 833-837.	0.5	6
510	Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302. Biology of Blood and Marrow Transplantation, 2013, 19, 481-485.	2.0	6
511	Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1531-1532.	2.0	6
512	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. Biology of Blood and Marrow Transplantation, 2017, 23, 1815-1816.	2.0	6
513	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. British Journal of Haematology, 2019, 186, 367-370.	2.5	6
514	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biology of Blood and Marrow Transplantation, 2020, 26, e305-e308.	2.0	6
515	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
516	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
517	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
518	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. Transplantation and Cellular Therapy, 2021, 27, 667.e1-667.e5.	1.2	6
519	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 650-657.	1.2	6
520	KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) â€" Pharmacodynamics and Updated Results. Blood, 2018, 132, 602-602.	1.4	6
521	Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.. Blood, 2005, 106, 3673-3673.	1.4	6
522	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. Blood, 2010, 116, 225-225.	1.4	6

#	Article	IF	Citations
523	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. Blood, 2014, 124, 319-319.	1.4	6
524	Should all unrelated donors for transplantation be matched?. Best Practice and Research in Clinical Haematology, 2008, 21, 79-83.	1.7	5
525	How closely related is graft-vs-leukemia to donor/recipient disparity?. Best Practice and Research in Clinical Haematology, 2010, 23, 525-528.	1.7	5
526	Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica, 2016, 101, e348-e351.	3.5	5
527	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graftâ€versusâ€host disease: analysis of BMT CTNâ€0201 and â€0901 samples. British Journal of Haematology, 2018, 182, 887-894.	2.5	5
528	Ruxolitinib combined with chemotherapy can eradicate chemorefractory central nervous system acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 187, e24-e27.	2.5	5
529	Low 5-year health care burden after umbilical cord blood transplantation. Blood Advances, 2021, 5, 853-860.	5.2	5
530	High risk of relapse with intermediate dose cytarabine for consolidation in young favourableâ€risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. British Journal of Haematology, 2021, 194, 140-144.	2.5	5
531	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
532	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood, 2019, 134, 4606-4606.	1.4	5
533	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. Blood, 2019, 134, 261-261.	1.4	5
534	Non-Myeloablative Umbilical Cord Blood Transplantation (UCBT): Low Transplant-Related Mortality in 59 High-Risk Adults.. Blood, 2004, 104, 825-825.	1.4	5
535	Impact of Cytogenetics on Outcome of Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Adults with AML.. Blood, 2004, 104, 830-830.	1.4	5
536	Single Versus Double Umbilical Cord Blood Transplantation (UCBT): Higher Risk of Acute Graft-Versus-Host Disease (GVHD) but Lower Transplant Related Mortality (TRM) in Recipients of Double UCBT.. Blood, 2006, 108, 435-435.	1.4	5
537	Umbilical Cord Blood Transplant after Reduced Intensity Conditioning Provides Outcomes Comparable HLA-Matched Siblings for Patients with High Risk and Advanced Acute Myeloid Leukemia.. Blood, 2006, 108, 606-606.	1.4	5
538	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. Blood, 2009, 114, 662-662.	1.4	5
539	Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia. Blood, 2011, 118, 355-355.	1.4	5
540	Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). Blood, 2015, 126, 2621-2621.	1.4	5

#	Article	IF	Citations
541	Protective Effect of Intestinal Blautia Against Neutropenic Fever in Allogeneic Transplant Recipients. Clinical Infectious Diseases, 2022, 75, 1912-1920.	5.8	5
542	Peripheral blood versus bone marrow for hematopoietic cell transplantation. Current Opinion in Oncology, 1998, 10, 112-118.	2.4	4
543	Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study. Biology of Blood and Marrow Transplantation, 2013, 19, S169.	2.0	4
544	Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM). Biology of Blood and Marrow Transplantation, 2013, 19, S154.	2.0	4
545	The donorâ€™s dilemma. Blood, 2014, 123, 3538-3539.	1.4	4
546	More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors. Biology of Blood and Marrow Transplantation, 2015, 21, S49-S50.	2.0	4
547	Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2016, 22, S50-S52.	2.0	4
548	Infection Followed by Graft-versus-Host Disease: Pathogenic Role of Antibiotics. Biology of Blood and Marrow Transplantation, 2017, 23, 1038-1039.	2.0	4
549	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a <scp>BMT CTN</scp> 0102 correlative study. British Journal of Haematology, 2017, 178, 816-819.	2.5	4
550	Can haploidentical transplantation meet all patients' needs?. Best Practice and Research in Clinical Haematology, 2018, 31, 410-413.	1.7	4
551	Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation. PLoS ONE, 2019, 14, e0220850.	2.5	4
552	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplantation, 2020, 55, 698-707.	2.4	4
553	Vancomycin use and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 2640-2643.	5.2	4
554	An alphaâ€defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graftâ€versus â€host disease. British Journal of Haematology, 2020, 189, 926-930.	2.5	4
555	COVID19 seroconversion in an unrelated stem cell donor. Bone Marrow Transplantation, 2021, 56, 723-725.	2.4	4
556	How old is too old for a transplant?. Best Practice and Research in Clinical Haematology, 2021, 34, 101243.	1.7	4
557	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer Journal, 2021, 11, 96.	6.2	4
558	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).. Blood, 2005, 106, 2064-2064.	1.4	4

#	Article	IF	Citations
559	Umbilical Cord Blood (UCB) Transplantation after Non-Myeloablative (NMA) Conditioning for Advanced Follicular Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Low Transplant-Related Mortality and High Progression-Free Survival.. Blood, 2005, 106, 2900-2900.	1.4	4
560	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. Blood, 2005, 106, 443-443.	1.4	4
561	KIR Ligand Absence in Recipients of Unrelated Donor (URD) Allogeneic Hematopoietic Cell Transplantation (HCT) Is Associated with Less Relapse and Increased Graft Versus Host Disease (GVHD).. Blood, 2006, 108, 171-171.	1.4	4
562	Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor Bone Marrow Transplantation.. Blood, 2006, 108, 172-172.	1.4	4
563	Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients.. Blood, 2008, 112, 1957-1957.	1.4	4
564	Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 657-657.	1.4	4
565	Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.. Blood, 2009, 114, 872-872.	1.4	4
566	Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens. Blood, 2013, 122, 550-550.	1.4	4
567	FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2014, 124, 322-322.	1.4	4
568	Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients. Blood, 2015, 126, 388-388.	1.4	4
569	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. Blood, 2016, 128, 2246-2246.	1.4	4
570	Response of 864 Patients to Steroids as Primary Therapy for Acute Gvhd at a Single Institution: Day 28 Response Is the Best Endpoint to Predict Transplant-Related Mortality.. Blood, 2009, 114, 1134-1134.	1.4	4
571	Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal. Blood, 2018, 132, 67-67.	1.4	4
572	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Blood, 2021, 138, 261-261.	1.4	4
573	Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 295-302.	2.0	4
574	Loss of microbiota-derived protective metabolites after neutropenic fever. Scientific Reports, 2022, 12, 6244.	3.3	4
575	Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2022, 28, 707.e1-707.e7.	1.2	4
576	The Antifibrinolytic Activity of Sulfamylon Solution. Plastic and Reconstructive Surgery, 1988, 82, 281-284.	1.4	3

#	Article	IF	Citations
577	Isolated relapse of acute myelogenous leukemia presenting as a gastric ulcer. American Journal of Hematology, 1991, 37, 270-273.	4.1	3
578	Less Acute Graft-Versus-Host Disease with Higher Mycophenolate Dose in. Biology of Blood and Marrow Transplantation, 2014, 20, S28-S29.	2.0	3
579	Multiple transmissions of chromosomally integrated human herpesvirusâ€6 in one family. Transplant Infectious Disease, 2018, 20, e12816.	1.7	3
580	Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual diseaseâ€negative first complete remission. American Journal of Hematology, 2018, 93, E381-E383.	4.1	3
581	Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. American Journal of Hematology, 2018, 93, 1014-1019.	4.1	3
582	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. Cancer, 2019, 125, 4033-4042.	4.1	3
583	Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 606-611.	2.0	3
584	Microbiome swings with repeated insults. British Journal of Haematology, 2020, 189, e94-e96.	2.5	3
585	Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graftâ€‹versusâ€‹host disease: An exploratory analysis. British Journal of Haematology, 2021, 192, e69-e73.	2.5	3
586	Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. Transplantation and Cellular Therapy, 2021, 27, 773.e1-773.e8.	1.2	3
587	AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkinâ€™s Lymphoma (NHL) and Multiple Myeloma.. Blood, 2004, 104, 2847-2847.	1.4	3
588	A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.. Blood, 2006, 108, 3111-3111.	1.4	3
589	New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. Blood, 2007, 110, 41-41.	1.4	3
590	Activating KIR (B Haplotype) in Unrelated Donors Improves Disease-Free Survival after HLA-Matched and Mismatched Allogeneic Transplantation for Acute Myeloid Leukemia: Implications for Donor Selection Using KIR Genotyping.. Blood, 2007, 110, 43-43.	1.4	3
591	Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. Blood, 2008, 112, 2168-2168.	1.4	3
592			

#	Article	IF	Citations
595	The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults â‰¥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries. Blood, 2012, 120, 1983-1983.	1.4	3
596	Similar Outcome Between Siblings, Unrelated Donors and Cord Blood After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in Complete Remission. Blood, 2012, 120, 1985-1985.	1.4	3
597	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. Blood, 2015, 126, 4375-4375.	1.4	3
598	Monocyte Subpopulation Recovery and Outcomes Following Hematopoietic Cell Transplantation. Blood, 2016, 128, 2232-2232.	1.4	3
599	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. Blood, 2016, 128, 679-679.	1.4	3
600	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2016, 128, 683-683.	1.4	3
601	Comparable Disease-Free and Overall Survival After â€œWell-Matchedâ€•Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research.. Blood, 2009, 114, 526-526.	1.4	3
602	Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802. Blood, 2017, 130, 72-72.	1.4	3
603	Severe/Life-Threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood - a Report from the BMT Survivor Study (BMTSS). Blood, 2020, 136, 12-13.	1.4	3
604	Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults. Blood, 2020, 136, 41-42.	1.4	3
605	Predictors and outcomes of flares in chronic graft-versus-host disease. Bone Marrow Transplantation, 2022, , .	2.4	3
606	Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. Blood Advances, 2022, 6, 2471-2479.	5.2	3
607	Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 509.e1-509.e11.	1.2	3
608	Identification and Purification of the Human Myeloid Differentiation Antigen Recognized by Monoclonal Antibody AHN-7. Journal of Leukocyte Biology, 1987, 41, 104-110.	3.3	2
609	Transplants for leukemia in relapse: When is the best time?. Best Practice and Research in Clinical Haematology, 2011, 24, 549-552.	1.7	2
610	Radiation Disasters: Role of the BMT Team. Biology of Blood and Marrow Transplantation, 2012, 18, S189-S192.	2.0	2
611	How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. American Journal of Hematology, 2013, 88, 826-827.	4.1	2
612	Allogeneic Transplant for Acute Biphenotypic Leukemia: Characteristics and Outcome in the CIBMTR Database. Biology of Blood and Marrow Transplantation, 2015, 21, S83.	2.0	2

#	Article	IF	Citations
613	Second Allogeneic Hematopoietic Cell Transplantation for Graft Failure: Poorer Outcomes for Neutropenic Graft Failure. Biology of Blood and Marrow Transplantation, 2015, 21, S166-S167.	2.0	2
614	Nonparametric Methods for Analyzing Recurrent Gap Time Data with Application to Infections After Hematopoietic Cell Transplant. Biometrics, 2016, 72, 535-545.	1.4	2
615	Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402. Biology of Blood and Marrow Transplantation, 2016, 22, S70-S71.	2.0	2
616	A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2352-2359.	1.3	2
617	Genomics of clonal evolution in a case of essential thrombocythemia. Leukemia and Lymphoma, 2018, 59, 497-500.	1.3	2
618	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. Leukemia, 2018, 32, 2706-2709.	7.2	2
619	Human Herpesvirus-6 Reactivation and Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, e5-e6.	2.0	2
620	Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 272-277.	2.0	2
621	Prognostic factors for clinical outcomes of patients with central nervous system leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 14, 240-245.	0.9	2
622	Hematopoietic Cell and Solid Organ Transplantation in the Same Patient: Long-Term Experience at the University of Minnesota. Transplantation and Cellular Therapy, 2021, 27, 87.e1-87.e6.	1.2	2
623	Infections in Recipients of Hematopoietic Cell Transplantation. , 2010, , 3821-3837.		2
624	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	1.4	2
625	High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3. Blood, 2019, 134, 3432-3432.	1.4	2
626	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. Blood, 2019, 134, 3323-3323.	1.4	2
627	Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease. Blood, 2020, 136, 14-14.	1.4	2
628	Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.. Blood, 2004, 104, 260-260.	1.4	2
629	Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).. Blood, 2005, 106, 1814-1814.	1.4	2
630	Negative Impact of KIR-Ligand Mismatch on Transplant-Related Mortality (TRM) in Umbilical Cord Blood Transplant (UCBT) Recipients.. Blood, 2005, 106, 2041-2041.	1.4	2

#	Article	IF	Citations
631	Impact of Long-Term Sequelae Diagnosed after Hematopoietic Cell Transplantation (HCT) on Health-Related Quality of Life (HRQL): A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2006, 108, 73-73.	1.4	2
632	Burdern of Long-Term Morbidity after Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study (BMTSS).. Blood, 2007, 110, 832-832.	1.4	2
633	Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival.. Blood, 2012, 120, 3092-3092.	1.4	2
634	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. Blood, 2013, 122, 159-159.	1.4	2
635	Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 3914-3914.	1.4	2
636	CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation. Blood, 2014, 124, 668-668.	1.4	2
637	Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2017-2017.	1.4	2
638	A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNÎ³ Production and Competition Between Donor NK and Recipient T Cells. Blood, 2015, 126, 566-566.	1.4	2
639	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. Blood, 2016, 128, 503-503.	1.4	2
640	High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation. Blood, 2016, 128, 5877-5877.	1.4	2
641	Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia. Cancer Treatment and Research, 2009, 144, 441-454.	0.5	2
642	Late Hospitalizations in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): Report From the Bone Marrow Transplant Study (BMTSS).. Blood, 2009, 114, 807-807.	1.4	2
643	ABO Mismatch Adversely Affects GvHD In Recipients of HLA Matched Unrelated Marrow or Peripheral Blood but Not Single or Double Umbilical Cord Blood Transplants. Blood, 2010, 116, 226-226.	1.4	2
644	What Predicts High Risk Acute Gvhd At Diagnosis?: Identification of Those At Highest Risk by a Novel Acute Gvhd Risk Score,. Blood, 2011, 118, 4062-4062.	1.4	2
645	Infections in Recipients of Hematopoietic Stem Cell Transplants. , 2015, , 3425-3439.e5.		2
646	Progressive Decline in Late Mortality after Hematopoietic Cell Transplantation (HCT) over 40 Years - a Report from BMTSS. Blood, 2016, 128, 691-691.	1.4	2
647	Severe hyperammonemia in chimeric antigen receptor T cells recipientâ€"unusual differential diagnosis of encephalopathy syndrome. Bone Marrow Transplantation, 2022, 57, 286-288.	2.4	2
648	Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients. Cancer Chemotherapy and Pharmacology, 2022, 89, 543-549.	2.3	2

#	Article	IF	Citations
649	High cutaneous amphiregulin expression predicts fatal acute <scp>graftâ€versusâ€host</scp> disease. Journal of Cutaneous Pathology, 2022, , .	1.3	2
650	CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 343.e1-343.e4.	1.2	2
651	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 455-462.	1.2	2
652	A dose-finding safety and feasibility study of oral activated charcoal and its effects on the gut microbiota in healthy volunteers not receiving antibiotics. PLoS ONE, 2022, 17, e0269986.	2.5	2
653	Bone Marrow Transplantation for Acute Leukemia. Investigative Radiology, 1987, 22, 839-846.	6.2	1
654	Planning and Response to Radiation Exposures. Biology of Blood and Marrow Transplantation, 2011, 17, 1262-1263.	2.0	1
655	Sirolimus/Mycophenolate Mofetil (MMF): Effective Calcineurin Inhibitor-Free GVHD Prophylaxis for Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S305.	2.0	1
656	Pharmacogenetics of steroid-responsive acute graft-versus-host disease. Clinical Transplantation, 2017, 31, e12949.	1.6	1
657	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplantation, 2018, 53, 1069-1071.	2.4	1
658	Complications After Hematopoietic Cell Transplantation. , 2018, , 1669-1684.e2.		1
659	Healthcare Resource Utilization (HCRU) and Costs Associated with Acute Graft-vs-Host Disease (aGVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (a-HSCT): A Retrospective Claims Database Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, S189-S190.	2.0	1
660	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (PregnylÂ®): A Phase I Study. Biology of Blood and Marrow Transplantation, 2019, 25, S240-S241.	2.0	1
661	Outpatient-to-Inpatient Transition Causes Marked Dysbiosis in Allogeneic Hematopoietic Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2019, 25, S47.	2.0	1
662	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplantation, 2019, 54, 490-493.	2.4	1
663	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Advances, 2020, 4, 2317-2324.	5.2	1
664	Weightâ€based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. European Journal of Haematology, 2021, 106, 205-212.	2.2	1
665	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2112-2112.	1.4	1
666	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2019, 134, 4585-4585.	1.4	1

#	Article	IF	Citations
667	Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.. Blood, 2004, 104, 2751-2751.	1.4	1
668	Increased Risk of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after Anti-Thymocyte Globulin (ATG) Non-Myeloablative (NMA) Conditioning for Umbilical Cord Blood Transplantation (UCBT).. Blood, 2005, 106, 3235-3235.	1.4	1
669	Flow Cytometric Analysis of Specimens by a Central Reference Laboratory in a Multi-Center Study: Factors Affecting Data Quality.. Blood, 2006, 108, 3385-3385.	1.4	1
670	Comparative Assessment of Weighting Comorbidities in the Hematopoietic Cell Transplantation (HCT) Specific Comorbidity Index (HCT-CI). Blood, 2008, 112, 798-798.	1.4	1
671	Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study.. Blood, 2009, 114, 528-528.	1.4	1
672	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 3506-3506.	1.4	1
673	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. Blood, 2010, 116, 908-908.	1.4	1
674	Graft-Versus-Host Disease (GVHD) Induced Graft-Versus-Leukemia (GVL) Effect: More Impact on Later Relapse and Disease-Free Survival Following Reduced Intensity Conditioning. Blood, 2011, 118, 1014-1014.	1.4	1
675	Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. Blood, 2014, 124, 2489-2489.	1.4	1
676	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	1.4	1
677	Validation of a Modified Comorbidity Index for Allogeneic Hematopoietic Cell Transplant. Blood, 2016, 128, 1167-1167.	1.4	1
678	Double Unit Myeloablative Umbilical Cord Blood (UCB) Transplantation in Adults & Adolescents: High Incidence of Engraftment and Low Transplant-Related Mortality.. Blood, 2004, 104, 826-826.	1.4	1
679	Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML.. Blood, 2009, 114, 665-665.	1.4	1
680	Association Between Genetic Variants in the Base Excision Repair Pathway and Outcomes After Hematopoietic Cell Transplant.. Blood, 2009, 114, 870-870.	1.4	1
681	Fludarabine-Associated Neurotoxicity After Hematopoietic Cell Transplantation (HCT): Clinical and Radiographic Features Predict Outcome.. Blood, 2009, 114, 2270-2270.	1.4	1
682	Delayed Platelet Recovery After Allogeneic Peripheral Blood, Marrow and Umbilical Cord Stem Cell Transplantation: Risk Factors and Clinical Outcomes.. Blood, 2009, 114, 867-867.	1.4	1
683	Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients.. Blood, 2009, 114, 525-525.	1.4	1
684	Burden of Morbidity in 10+ Year Survivors of Hematopoietic Cell Transplantation (HCT): A Report From the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2011, 118, 841-841.	1.4	1

#	Article	IF	Citations
685	Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 Ã— CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML). Blood, 2012, 120, 256-256.	1.4	1
686	Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia.. Blood, 2012, 120, 3081-3081.	1.4	1
687	Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study. Blood, 2012, 120, 3841-3841.	1.4	1
688	HLA Haplotype Frequency Analysis Within India: Pre-Requisite For Bone Marrow Donor Registry and Cord Blood Bank Planning. Blood, 2013, 122, 5607-5607.	1.4	1
689	Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival. Blood, 2018, 132, 3353-3353.	1.4	1
690	SEMIPARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. Statistica Sinica, 2019, 29, 1489-1509.	0.3	1
691	Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2019, 134, 2036-2036.	1.4	1
692	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). Blood, 2019, 134, 707-707.	1.4	1
693	Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS). Blood, 2019, 134, 3298-3298.	1.4	1
694	Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS). Blood, 2019, 134, 699-699.	1.4	1
695	Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis. Blood, 2021, 138, 414-414.	1.4	1
696	Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials. Blood, 2021, 138, 259-259.	1.4	1
697	KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries. Blood, 2021, 138, 419-419.	1.4	1
698	Transplantation provides superior survival high risk myeloid malignancies in older patients. Leukemia and Lymphoma, 2022, 63, 2494-2498.	1.3	1
699	Major Prognostic Factors in RAEB. American Journal of Clinical Pathology, 1984, 81, 546-546.	0.7	0
700	Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution. American Journal of Health-System Pharmacy, 1992, 49, 608-612.	1.0	0
701	Management of graft-versus-host disease. Transfusion Science, 1994, 15, 231-242.	0.6	0
702	Rash and GI Symptoms on Day +36. Biology of Blood and Marrow Transplantation, 2007, 13, 1405-1406.	2.0	0

#	Article	IF	Citations
703	Blood and marrow transplant organizations. , 2009, , 513-521.		0
704	John H. Kersey, M.D.. Biology of Blood and Marrow Transplantation, 2013, 19, 1001.	2.0	0
705	Pre-Transplant Consolidation Chemotherapy Does Not Improve Outcomes Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) for Acute Myeloid Leukemia (AML) in CR1. Biology of Blood and Marrow Transplantation, 2013, 19, S231.	2.0	0
706	Similar Survival in Patients with Acute Myeloid Leukemia Relapsing After Matched Related Donor and Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S113.	2.0	0
707	Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia (ALL): Impact of Conditioning Intensity, Tyrosine Kinase Inhibitors (TKI) and Minimal Residual Disease (MRD). Biology of Blood and Marrow Transplantation, 2013, 19, S223.	2.0	0
708	Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium. Biology of Blood and Marrow Transplantation, 2013, 19, S338.	2.0	0
709	High-Resolution Donor-Recipient HLA Matching Does Not Influence Acute or Chronic Gvhd in Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S140.	2.0	0
710	Hematopoietic Cell Transplantation in Patients with Systolic Heart Failure: Can It be Done?. Biology of Blood and Marrow Transplantation, 2014, 20, S37.	2.0	0
711	Pre-Transplant Serum Biomarkers Predict Early Relapse in Classical Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S144-S145.	2.0	0
712	New Models of Therapy: When Acute Leukemia BecomesÂChronic. Biology of Blood and Marrow Transplantation, 2015, 21, 1856-1857.	2.0	0
713	FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, S86-S87.	2.0	0
714	Clostridium difficile Infection Among Allogeneic Hematopoietic Stem Cell and Solid Organ Transplant Recipients: Differences in Rates and Outcomes. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
715	Allogeneic hematopoietic cell transplantation in morphologic leukemiaâ€free aplastic state. American Journal of Hematology, 2017, 92, E549-E552.	4.1	0
716	Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?. Biology of Blood and Marrow Transplantation, 2017, 23, 1804-1808.	2.0	0
717	Favorable Outcomes in Patients with Pre-Transplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci. Biology of Blood and Marrow Transplantation, 2018, 24, S84-S85.	2.0	0
718	Late Mortality in Patients Transplanted for Inborn Errors of Metabolism (IEM) â€“ A Report From the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). Biology of Blood and Marrow Transplantation, 2018, 24, S28.	2.0	0
719	Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials. Biology of Blood and Marrow Transplantation, 2018, 24, S177-S178.	2.0	0
720	RNA Sequencing of Intestinal Biopsies Expands the T Cell-Centric Paradigm of Steroid-Refractory Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, S295.	2.0	0

#	Article	IF	Citations
721	Pre-Engraftment Gut Colonization with Enterococcus Casseliflavus Improves Survival after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S360-S361.	2.0	0
722	HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). Biology of Blood and Marrow Transplantation, 2019, 25, S59-S60.	2.0	0
723	Healthcare Costs in Patients with Lethal Acute Graft-Versus-Host Disease (aGVHD) Post Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) in the United States. Biology of Blood and Marrow Transplantation, 2019, 25, S244.	2.0	0
724	Gut Dysbiosis Increases Gut Barrier Damage during Anti-Leukemia Chemotherapy: Implications for Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, S142-S143.	2.0	0
725	Haptoglobin genotype and gut barrier-related complications of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 464-466.	2.4	0
726	Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplantation, 2020, 55, 833-835.	2.4	0
727	No Evidence for Long-Term Persistence of HHV-6 Viremia after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, S332.	2.0	0
728	Circulating bacterial DNA and neutropenic fever during antiâ€leukaemia chemotherapy. British Journal of Haematology, 2020, 191, e55-e58.	2.5	0
729	Increasing Use of Potentially Inappropriate Medications in Older Allogeneic HCT Recipients Leads to Higher NRM. Biology of Blood and Marrow Transplantation, 2020, 26, S133-S134.	2.0	0
730	Pediatric Late-Onset Acute and Chronic Graft-Versus-Host Disease: A Single Center Cohort Study 2007-2017. Biology of Blood and Marrow Transplantation, 2020, 26, S175-S176.	2.0	0
731	MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients. Biology of Blood and Marrow Transplantation, 2020, 26, S10-S11.	2.0	0
732	39901 Breaking down silos to synergize clinical trial development and initiation: The Clinical Research Support Center, University of Minnesota. Journal of Clinical and Translational Science, 2021, 5, 108-109.	0.6	0
733	10040 Proactive and responsive COVID-19 multidisciplinary research support through the University of Minnesotaâ€™s Clinical Research Support Center. Journal of Clinical and Translational Science, 2021, 5, 108-108.	0.6	0
734	Transfusion burden following reduced intensity allogeneic hematopoietic cell transplantation: Impact of donor type. Transfusion, 2021, 61, 2064-2074.	1.6	0
735	Quantitative serum PCR argues against longâ€term persistence of HHVâ€6 viremia after umbilical cord blood transplantation. Transplant Infectious Disease, 2021, 23, e13555.	1.7	0
736	Current Controversies in Bone Marrow Transplantation. Annals of Internal Medicine, 2000, 133, 932.	3.9	0
737	Health Care Utilization by Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2004, 104, 2196-2196.	1.4	0
738	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. Blood, 2004, 104, 1817-1817.	1.4	0

#	Article	IF	Citations
739	Depression, Somatic Distress and Anxiety in Adult Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2004, 104, 231-231.	1.4	0
740	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. Blood, 2004, 104, 2148-2148.	1.4	0
741	Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.. Blood, 2005, 106, 842-842.	1.4	0
742	Impact of Chronic Graft Versus Host Disease (cGVHD) on the Health Status of Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2005, 106, 702-702.	1.4	0
743	NK Cell KIR Reconstitution after Allogeneic Hematopoietic Cell Transplant (HCT) Is Affected by T Cell Number and Function.. Blood, 2005, 106, 1406-1406.	1.4	0
744	Diabetes, Hypertension and Cardiovascular Events in Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2005, 106, 699-699.	1.4	0
745	Interleukin-1 Î± Genotype and Outcome of Unrelated Donor BMT for CML.. Blood, 2005, 106, 2057-2057.	1.4	0
746	Health-Risk Behaviors among Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2005, 106, 748-748.	1.4	0
747	Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell Transplantation (SCT).. Blood, 2006, 108, 2999-2999.	1.4	0
748	Reduced Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor.. Blood, 2007, 110, 331-331.	1.4	0
749	Pharmacogenetics of Mycophenolate Mofetil in Patients Undergoing Hematopoietic Cell Transplantation (HCT).. Blood, 2007, 110, 3010-3010.	1.4	0
750	The Predictive Value of the Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index (CI) in Recipients of Umbilical Cord Blood (UCB) Transplantation.. Blood, 2007, 110, 5065-5065.	1.4	0
751	Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies.. Blood, 2007, 110, 2028-2028.	1.4	0
752	Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.. Blood, 2007, 110, 3055-3055.	1.4	0
753	Similar Risks for Late-Onset Chronic Kidney Disease in Myeloablative and Reduced-Intensity Allogeneic Hematopoietic Cell Transplant Survivors.. Blood, 2007, 110, 3008-3008.	1.4	0
754	Allogeneic Stem Cell Transplantation (AlloSCT) for the Treatment of Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR).. Blood, 2007, 110, 3057-3057.	1.4	0
755	Graft Composition and Outcomes in Unrelated Donor Transplantation.. Blood, 2007, 110, 3065-3065.	1.4	0
756	Prolonged Survival in Adults with Acute Lymphoblastic Leukemia (ALL) Following Reduced Intensity Conditioning and Allogeneic Transplantation. Blood, 2008, 112, 4415-4415.	1.4	0

#	Article	IF	Citations
757	Negative Effect of KIR Alloreactivity in Recipients of Umbilical Cord Blood Transplantation Depends on Transplantation Conditioning Intensity. Blood, 2008, 112, 152-152.	1.4	0
758	Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).. Blood, 2008, 112, 1116-1116.	1.4	0
759	Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT). Blood, 2008, 112, 795-795.	1.4	0
760	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Similar Efficacy of Non-Myeloablative and Myeloablative Conditioning; Long-Term Evaluation From the University of Minnesota.. Blood, 2009, 114, 3385-3385.	1.4	0
761	Allogeneic Donor NK Cell Infusion and IL-2 for Patients with Refractory B-Cell Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3036-3036.	1.4	0
762	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. Blood, 2010, 116, 898-898.	1.4	0
763	Relapse of Lymphoma After Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome.. Blood, 2010, 116, 4503-4503.	1.4	0
764	Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium. Blood, 2010, 116, 220-220.	1.4	0
765	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors â€“ An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
766	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 211-211.	1.4	0
767	Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia. Blood, 2010, 116, 213-213.	1.4	0
768	Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of CD20 Expression In Both Adult and Pediatric Acute Lymphoblastic Leukemia.. Blood, 2010, 116, 1681-1681.	1.4	0
769	Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium. Blood, 2010, 116, 393-393.	1.4	0
770	Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. Blood, 2010, 116, 3531-3531.	1.4	0
771	NK Education: Disassociation Between Recovery of Cytoxicity and Cytokine Production In NK Cells After Allogeneic Transplantation.. Blood, 2010, 116, 1462-1462.	1.4	0
772	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	1.4	0
773	Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium. Blood, 2011, 118, 1988-1988.	1.4	0
774	Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2011, 118, 494-494.	1.4	0

#	Article	IF	Citations
775	IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,. Blood, 2011, 118, 3611-3611.	1.4	0
776	Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2011, 118, 2027-2027.	1.4	0
777	Unrelated Cord Blood Transplantation (UCBT) in Adult and Pediatric Acute Lymphoblastic Leukemia: Impact of Minimal Residual Disease on Relapse and Survival,. Blood, 2011, 118, 4114-4114.	1.4	0
778	The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients,. Blood, 2011, 118, 4148-4148.	1.4	0
779	Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients â‰¥55 Years. Blood, 2011, 118, 1015-1015.	1.4	0
780	A Population-Based Study In Acute Myeloid Leukemia (AML) Suggests Improved Overall Survival (OS) up to Age 80 with Intravenous Therapy: 2000â€“2007 Data From the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry In the United States (US),. Blood, 2011, 118, 3589-3589.	1.4	0
781	Association Between Genetic Variants in Immune Response Genes and Outcomes After Hematopoietic Cell Transplantation. Blood, 2011, 118, 3049-3049.	1.4	0
782	Elevated Absolute Lymphocyte Counts Following Acute Graft Vs. Host Disease Treatment Is Associated with Therapeutic Responses and Lower Non-Relapse Mortality Following Umbilical Cord Blood Transplant,. Blood, 2011, 118, 4085-4085.	1.4	0
783	Initial Clinical Findings From a Population-Based Study of Adult Myelodysplastic Syndrome: Discordance Between World Health Organization (WHO) Classifications. Blood, 2011, 118, 1733-1733.	1.4	0
784	Are IPSS-R and IPSS Cytogenetic Risk Stratification Informative At the Time of Allogeneic Hematopoietic Cell Transplantation?. Blood, 2012, 120, 1400-1400.	1.4	0
785	Increased Relapse Associated with Mixed Donor-Donor Chimerism Following Double Umbilical Cord Blood Transplantation (dUCBT). Blood, 2012, 120, 358-358.	1.4	0
786	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	1.4	0
787	Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch. Blood, 2012, 120, 1976-1976.	1.4	0
788	Discordant World Health Organization (WHO) Classifications In a Population-Based Study Of Adult Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 1546-1546.	1.4	0
789	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
790	Recipient HLA-C1 Enhances The Clinical Advantage Of Killer-Cell Immunoglobulin-Like Receptor B haplotype Donors In Myeloablative Unrelated Transplantation For Acute Myelogenous Leukemia. Blood, 2013, 122, 549-549.	1.4	0
791	Unrelated Umbilical Cord Blood Transplantation: Characteristics and Outcomes In Older Patients With Hematological Malignancies In Europe and United States: A Eurocord/European Group For Blood and Marrow Transplantation (EBMT) and Center For International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2013, 122, 3339-3339.	1.4	0
792	Validation and Refinement Of The Disease Risk Index For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of 13,131 Patients From The Center For International Blood & Marrow Transplant Research. Blood, 2013, 122, 548-548.	1.4	0

#	Article	IF	Citations
793	Higher CSA Levels After Umbilical Cord Blood Transplant For Acute Leukemia Result In Improved Survival. Blood, 2013, 122, 2097-2097.	1.4	0
794	Survival Of AML Patients Relapsing After Allogeneic Stem Cell Transplantation: A Center For International Blood and Marrow Transplant Research Study. Blood, 2013, 122, 2072-2072.	1.4	0
795	Phosphoramide Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation. Blood, 2013, 122, 5461-5461.	1.4	0
796	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. Blood, 2013, 122, 4614-4614.	1.4	0
797	Long-Term Health-Related Outcomes In Survivors Of Childhood Hematopoietic Cell Transplantation (HCT): A Report From The Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2013, 122, 553-553.	1.4	0
798	Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes. Blood, 2013, 122, 302-302.	1.4	0
799	Do Blood Transfusions Cause Pulmonary Complications Following Hematopoietic CELL Transplantation?. Blood, 2014, 124, 2477-2477.	1.4	0
800	Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT). Blood, 2014, 124, 1153-1153.	1.4	0
801	Clonal Expansion of Adaptive NK Cells and NKG2C+CD57+ KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation. Blood, 2014, 124, 181-181.	1.4	0
802	Unrelated Donor KIR B/X Genotype Reduces Relapse and Improves Progression-Free Survival after HLA-Matched Allogeneic Transplantation for Relapsed/Refractory Non-Hodgkin Lymphoma. Blood, 2014, 124, 670-670.	1.4	0
803	What Predicts Success for a New Composite Endpoint: Graftâ€“versus-Host Disease-Free and Relapse-Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation?. Blood, 2014, 124, 429-429.	1.4	0
804	A Biomarker Algorithm Defines Onset Grades of Acute Graft-Vs-Host Disease with Distinct Non-Relapse Mortality. Blood, 2014, 124, 661-661.	1.4	0
805	Day 21 Chimerism Is a Critical Prognostic Factor for Graft Failure and Survival in Recipients of Myeloablative Conditioning and Umbilical Cord Blood (UCB) Transplantation. Blood, 2014, 124, 3867-3867.	1.4	0
806	Acute Graft Versus Host Disease after Donor Lymphocyte Infusion: A Single Center Analysis. Blood, 2014, 124, 5807-5807.	1.4	0
807	Transplantation Related Toxicity and Mortality in Older Autologous Hematopoietic Cell Transplantation Recipients. Blood, 2014, 124, 3965-3965.	1.4	0
808	Pharmacokinetic Modeling of Fludarabine to Control Exposure and Improve Outcomes after Reduced Intensity Conditioning Transplantation. Blood, 2014, 124, 3869-3869.	1.4	0
809	Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study. Blood, 2014, 124, 2572-2572.	1.4	0
810	Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2014, 124, 683-683.	1.4	0

#	Article	IF	Citations
811	Risk Factors for Acute and Chronic Gvhd after Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Relative Risks with Umbilical Cord Blood (UCB) and Matched Related Donors (MRD). Blood, 2014, 124, 189-189.	1.4	0
812	Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers. Blood, 2015, 126, 928-928.	1.4	0
813	Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2015, 126, 1934-1934.	1.4	0
814	Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB). Blood, 2016, 128, 4590-4590.	1.4	0
815	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. Blood, 2016, 128, 63-63.	1.4	0
816	Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2. Blood, 2016, 128, 823-823.	1.4	0
817	Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab. Blood, 2016, 128, 3030-3030.	1.4	0
818	Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study. Blood, 2016, 128, 684-684.	1.4	0
819	Umbilical Cord Blood Transplantation and Delay Engraftment Are Associated with Increased Risks of Diffuse Alveolar Hemorrhage. Blood, 2016, 128, 2222-2222.	1.4	0
820	Allogeneic Hematopoietic Cell Transplantation for Elderly Patients: Prognosis Determined By Disease Risk Index. Blood, 2016, 128, 2305-2305.	1.4	0
821	Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant. Blood, 2016, 128, 515-515.	1.4	0
822	UCB HCT in FLT3+ AML. Oncotarget, 2017, 8, 81733-81734.	1.8	0
823	Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood: a Report from the BMT Survivor Study-2 (BMTSS-2). Blood, 2017, 130, 672-672.	1.4	0
824	Pre-Engraftment Gut Colonization with Enterococcus Casseliflavus Improves Survival after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 813-813.	1.4	0
825	5 Year Health Care Burden after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Impact of Graft Source. Blood, 2018, 132, 367-367.	1.4	0
826	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	1.4	0
827	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. Blood, 2018, 132, 3456-3456.	1.4	0
828	Venous Thromboembolism in Blood or Marrow Transplant (BMT) Survivors: A Report from BMT Survivor Study (BMTSS). Blood, 2018, 132, 823-823.	1.4	0

#	Article	IF	Citations
829	Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) â€" Results of the BMT Survivor Study (BMTSS). Blood, 2018, 132, 2127-2127.	1.4	0
830	Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 39-39.	1.4	0
831	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Blood, 2019, 134, 412-412.	1.4	0
832	Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index. Blood, 2019, 134, 4603-4603.	1.4	0
833	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). Blood, 2019, 134, 2009-2009.	1.4	0
834	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) â€" Long-Term Follow-up of a Phase 2a Study (KD025-208). Biology of Blood and Marrow Transplantation, 2020, 26, S187-S188.	2.0	0
835	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. Blood, 2021, 138, 1811-1811.	1.4	0
836	Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) Treatment. Blood, 2021, 138, 1744-1744.	1.4	0
837	Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1832-1832.	1.4	0
838	Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. Blood, 2021, 138, 3923-3923.	1.4	0
839	Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. Blood, 2021, 138, 484-484.	1.4	0
840	Circulating Metabolomics Suggest Neutropenic Fever As a Metabolic Derangement Related to Intestinal Tissue Damage and Gut Dysbiosis. Blood, 2021, 138, 688-688.	1.4	0
841	Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). Blood, 2021, 138, 2905-2905.	1.4	0
842	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 44-46.	1.4	0
843	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 47-48.	1.4	0
844	Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. Blood, 2020, 136, 17-18.	1.4	0
845	Pre-Transplant Fecal Microbiome Characteristics Are Associated with Subsequent Development of Chronic Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2022, 28, S57-S58.	1.2	0
846	Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials. Transplantation and Cellular Therapy, 2022, 28, S60-S61.	1.2	0

#	Article	IF	Citations
847	Prevalence and Predictors of Pre-HCT Frailty in Autologous and Allogeneic Hematopoietic Cell Transplant Recipients. Transplantation and Cellular Therapy, 2022, 28, S153.	1.2	0
848	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Transplantation and Cellular Therapy, 2022, 28, S58-S59.	1.2	0
849	Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	2.4	0